Scandion Oncology CEO Newsletter autumn 2019
Dear Scandion Oncology shareholder, Scandion Oncology is heading towards an exciting future where we will, hopefully, deliver a new cancer treatment to the market. One that can help overcome chemotherapy resistance - an accomplishment that truly would mark a new dawn for modern cancer treatment.Mastering the global challenge of eradicating drug resistance Two months have now passed since we finalized our successful rights issue. The right issue provided Scandion Oncology with the financial means to conduct the two planned clinical phase II trials in cancer patients with metastatic